Experiment 626307
Worktypes
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Oenothera biennis (ONAGRACEAE) |
| Citation | YOSHIMOTO-FURUIE,K: YOSHIMOTO,K: TANAKA,T: SAIMA,S: KIKUCHI,Y: SHAY,J: HORROBIN,DF: ECHIZEN,H:. (1999). EFFECTS OF ORAL SUPPLEMENTATION WITH EVENING PRIMROSE OIL FOR SIX WEEKS ON PLASMA ESSENTIAL FATTY ACIDS AND UREMIC SKIN SYMPTOMS IN HEMODIALYSIS PATIENTS.. 81(2) |
| Amount utilized | |
| Compound isolated | |
| Disease | TO STUDY WHETHER AN ORAL SUPPLEMENTATION WITH OMEGA-6(N-6) EFAS WOULD RESTORE DERANGED PLASMA EFAS AND AMELIOARATE SKIN SYMPTOMS, 9 AND 7 DIALYSIS PATIENTS WERE RANDOMLY ASSIGNED TO RECEIVE EITHER GAMMA-LINOLENIC ACID (GLA)-RICH EVENING PRIMROSE OIL (EPO) OR LINOLEIC ACID (LA) (2 G/DAY EACH) FOR 6 WEEKS. PLASMA CONCENTRATIONS OF EFA WERE ANALYZED BY GAS CHROMATOGRAPHY AND UREMIC SKIN SYMPTOMS WERE ASSESSED FOR DRYNESS, PRURITUS AND ERYTHEMA BY QUESTIONNAIRE AND VISUAL INSPECTION IN A DOUBLE-BLIND MANNER. THE PATIENTS GIVEN EPO EXHIBITED A SIGNIFICANT (P <0.05) INCREASE IN PLASMA DIHOMO-GAMMA-LINOLENIC ACID (A PRECURSOR OF ANTI-INFLAMMATORY PROSTAGLANDIN E1) WITH NO CONCOMITANT CHANGE IN PLASMA ARACHIDONIC ACID (A PRECURSOR OF PRO-INFLAMMATORY PROSTAGLANDIN E2 AND LEUKOTRIENE B4). IN CONTRAST, THOSE GIVEN LA EXHIBITED A SIGNIFICANT (P <0.05) INCREASE IN LA BUT NOT IN ANY OTHER N-6 EFAS, WHEREAS THEY EXHIBITED A SIGNIFICANT (P <0.05) DECREASE IN PLASMA DOCOSAHEXAENOIC ACID. THE PATIENTS GIVEN EPO SHOWED A SIGNIFICANT (P Z0.05) IMPROVEMENT IN THE SKIN SCORES FOR THE THREE DIFFERENT UREMIC SKIN SYMPTOMS OVER THE BASELINE VALUES AND A TREND TOWARD A GREATER IMPROVEMENT (0.05) < P < 0.1) IN PRURITUS SCORES THAN THOSE GIVEN LA. RESULTS INDICATE THAT GLA-RICH EPO WOULD BE A MORE FAVORABLE SUPPLEMENTAL SOURCE THAN LA IN TERMS OF SHIFTING EICOSANOID METABOLISM TOWARD A LESS INFLAMMATION STATUS THROUGH MODIFYING PLASMA CONCENTRATIONS OF THEIR PRECURSOR N-6 EFAS. FURTHER STUDIES ARE REQUIRED TO CONFIRM THE EFFICACY AND SAFETY OF EPO THERAPY FOR THE TREATMENT OF UREMIC PRURITUS. |
| Dose amount | 1.8 GM |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Extract | SEED OIL |
| Gender | GIVEN TO BOTH SEXES |